Biotech RadarJobs updated

COMPANY

Ashvattha Therapeutics

HQ: Redwood City, CA source · avttx.com ↗

Clinical Phase 2

Ashvattha Therapeutics is advancing a new class of clinical-stage nanomedicine therapeutics that traverse tissue barriers to selectively target activated cells in regions of inflammation. From company website Source · Oct 13, 2026

Keywords: therapeutics Neovascular Age-related Macular Degeneration Diabetic Macular Edema Amyotrophic Lateral Sclerosis Parkinson Disease Alzheimer Disease Multiple Sclerosis COVID-19 D-4517.2 OP-101

Location: Redwood City, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

$50.0MRaised (2 yrs)5Trials (company is sponsor)

Timeline

  1. Trial start Phase 1: Study Evaluating Safety & Tolerability of Migaldendranib in Healthy Volunteers source ↗
  2. Raise Private equity round: $50M (total, as published), announced Jan 13, 2025. Source: company release on GlobeNewswire. source ↗
  3. Trial start Phase 1/Phase 2: Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers source ↗
  4. Trial start Phase 2: Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME source ↗
  5. Trial start Phase 1: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of D-4517.2 After Subcutaneous Administration in Healthy Participants source ↗
  6. Trial start Phase 2: A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) Patients source ↗

Funding

Raised: $50.0M. Last 2 years.

Clinical trials (lead sponsor) 5

RecordTitlePhaseStatusStartPrimary completion
NCT07370155Study Evaluating Safety & Tolerability of Migaldendranib in Healthy VolunteersPhase 1Active, not recruitingJan 29, 2026Mar 5, 2026 (actual)
NCT05387837Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DMEPhase 2Active, not recruitingAug 31, 2022May 9, 2025 (estimated)
NCT05395624Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy VolunteersPhase 1/Phase 2RecruitingFeb 2, 2023Jan 1, 2026 (estimated)
NCT04458298A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) PatientsPhase 2TerminatedAug 11, 2020Aug 12, 2022 (actual)
NCT05105607A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of D-4517.2 After Subcutaneous Administration in Healthy ParticipantsPhase 1CompletedJan 11, 2022Aug 31, 2022 (actual)
Feedback